Lerapolturev is under clinical development by Istari Oncology and currently in Phase II for Bladder Cancer. According to GlobalData, Phase II drugs for Bladder Cancer have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lerapolturev’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Lerapolturev overview

Lerapolturev is under development for the treatment of recurrent glioblastoma (recurrent grade IV glioma), supratentorial glioma, melanoma and triple negative breast cancer, hormone positive breast cancer, anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, anaplastic pleomorphic xanthoastrocytoma, ependymoma, medulloblastoma, or atypical teratoid/rhabdoid tumor, bladder cancer, muscle invasive bladder cancer, urothelial carcinoma, HER2+ breast cancer, gastric, esophageal, and non-muscle invasive bladder cancer. The vaccine comprises of live attenuated, nonpathogenic oncolytic virus containing the oral poliovirus Sabin type 1 in which the internal ribosomal entry site (IRES) is replaced with the IRES from human rhinovirus type 2 (HRV2), with potential antineoplastic activity. The vaccine is administered through intra-tumoral, intravesical and intralesional route. It was also under development for head and neck cancer squamous cell carcinoma, oropharyngeal cancer, oral cavity (mouth) cancer, hypopharyngeal cancer, laryngeal cancer.

Istari Oncology overview

Istari Oncology, Inc., a biotechnology company that focused on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma. The company is headquartered in United States.

For a complete picture of Lerapolturev’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.